Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Portfolio Pulse from Avi Kapoor
Zscaler, Inc. (ZS) shares fell by 10.1% following its Q2 earnings report, despite better-than-expected results. Other stocks showed significant movement, with BioVie Inc. (BIVI) and Adial Pharmaceuticals, Inc. (ADIL) among the top gainers. Losers included GigCapital5, Inc. (GIA) and Fisker Inc. (FSR), with FSR dropping 44.6% due to concerns about its going concern status.
March 01, 2024 | 6:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fisker Inc. shares plummeted 44.6% to $0.4035 after reporting preliminary Q4 revenue below estimates and expressing doubts about its going concern status.
Fisker Inc.'s significant stock price drop is due to its preliminary Q4 revenue miss and the announcement of substantial doubt about its ability to continue, raising serious concerns among investors.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100
NEGATIVE IMPACT
Zscaler's stock fell 10.1% to $217.43 despite reporting better-than-expected Q2 earnings and sales, with optimistic FY2024 guidance.
The drop in Zscaler's stock price despite positive earnings and guidance suggests market expectations were higher or concerns about future growth. The significant price movement indicates a strong reaction to the earnings report.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Adial Pharmaceuticals gained 68.4% to $3.4350 after being awarded a new patent for AD04, aimed at treating opioid use disorder.
The sharp increase in Adial Pharmaceuticals' stock price is attributed to the new patent for AD04, signaling potential market exclusivity and optimism about its commercial prospects.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
BioVie Inc. shares surged 96.1% to $2.4319 after demonstrating potential improvements in Parkinson's and Alzheimer's treatments.
BioVie's significant stock price increase is likely due to the positive results from its treatments for Parkinson's and Alzheimer's, indicating potential market success and investor optimism.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90